Zaven Boyrazian explores three FTSE 100 shares with impressive track records of navigating through even the worst economic ...

Americans may end up paying more for their medicines as well as facing shortages of drugs they need. So it's possible there ...

China’s response to new United States (U.S.) tariffs could complicate the supply of important medicines, an analysis of data ...

U.K. regulators cleared a multiple myeloma drug GSK withdrew from market three years ago. Elsewhere, an investment firm pressed Elevation Oncology to liquidate and the FDA relaxed risk monitoring ...

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep.

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in ...

The UK on Thursday authorized GSK’s Blenrep to treat certain multiple myeloma patients in two different regimens, marking the ...

GSK received approval from U.K.'s medicines regulatory body to bring its blood-cancer blockbuster candidate Blenrep back to the market, enabling the British pharma giant to expand its oncology ...

GSK’s blood cancer drug Blenrep won regulatory approval in the U.K., marking the medicine’s return to the market after it was ...

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

Some justices may be skeptical of a bid by GSK, Pfizer and others to overturn ruling allowing lawsuits to proceed over claims ...